Viking Global
Work Here?
About Viking Global
Industries
Venture Capital
Financial Services
Company Size
51-200
Company Stage
N/A
Total Funding
$16.8B
Headquarters
Greenwich, Connecticut
Founded
1999
Overview
Simplify's Take
What believers are saying
- Viking's investment in Valsoft highlights growth potential in vertical market software.
- Their funding in Magenta Medical supports accelerated market entry for innovative heart pumps.
- Collaboration with AbCellera leverages expertise in antibody drug discovery and development.
What critics are saying
- Increased competition in heart pumps may impact Magenta Medical's market position.
- Biotech sector's competitive landscape could challenge new antibody drug programs' success.
- Multiple funding rounds expose Viking to financial risks if companies underperform.
What makes Viking Global unique
- Viking Global Investors focuses on vertical market software, a growing and consolidating sector.
- They invest in innovative medical devices with FDA Breakthrough Device Designation potential.
- Their collaboration with AbCellera targets early-stage biotech investments in immunology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$16841.8M
Above
Industry Average
Funded Over
0 Rounds
Benefits
Health Insurance
Dental Insurance
Performance Bonus
Meal Benefits
Hybrid Work Options
Company News
New equity funding from Portage Capital Solutions, Viking Global Investors, and PROPELR Growth underscores Valsoft's leadership and growth potential MONTRÉAL, QC / ACCESSWIRE / December 26, 2024 /Valsoft Corporation Inc. ("Valsoft"), a Canadian company ...
Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today anno
Magenta Medical has secured $105 million in a financing round led by Novo Holdings, with participation from Viking Global Investors, RA Capital Management, and existing investors like OrbiMed and New Enterprise Associates. The funds will support US clinical programs and FDA approval pursuits for the Elevate heart pump, designed for high-risk percutaneous coronary interventions. The Elevate System, noted for its small size and high power, has received Breakthrough Device Designation from the FDA.
Israeli startup aims to compete with U.S. heart-pump pioneer Abiomed, now owned by Johnson & Johnson. But analysts say the market has lots of room to grow.
Antheia announced $17 million in new funding through a government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) and matching support from new strategic investors. The funding includes a non-dilutive two-year project agreement up to $11 million from BioMaP and additional investment from In-Q-Tel, Inc. (IQT), Echo Investment Capital (Echo), and existing investors like Viking Global Investors.
Viking Global is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Viking Global
Industries
Venture Capital
Financial Services
Company Size
51-200
Company Stage
N/A
Total Funding
$16.8B
Headquarters
Greenwich, Connecticut
Founded
1999
Viking Global is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today